AGe-PD: Influence of Age and Genetic Status on the Progression and Treatment Response of Parkinson’s Disease

AGe-PD: Influence of Age and Genetic Status on the Progression and Treatment Response of Parkinson’s Disease - AGe-PD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028134

Enrollment

200

Registered

2022-03-17

Start date

2022-01-20

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: Parkinson’s patients with deep brain stimulation (DBS) and a young age at onset (45 years)

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Parkinson's disease

Exclusion criteria

Exclusion criteria: age <18 years

Design outcomes

Primary

Measure	Time frame
data of clinical routine: evaluation appointment, operation protocol, appointments after 3 and 12 month after the surgery. further annual follow up. Data used in the registry are clinical scores (UPDRS, BDI, QUIP, Strakstein-Apathie-Skala, DemTect, MMST, PDQ39), pre and postoperative videoducumentation, comorbidities, labresults, Levodopaequiveleny dosage, cerebral MRI and CT, localization date of the electrodes, adverse events and severe adverse events, side effects of the stimulation, settings of deep brain stimulation (chosen contacts, impedance, amplitude, pulse width, frequence) from the clinical routine.	—

Measure

Time frame

data of clinical routine: evaluation appointment, operation protocol, appointments after 3 and 12 month after the surgery. further annual follow up. Data used in the registry are clinical scores (UPDRS, BDI, QUIP, Strakstein-Apathie-Skala, DemTect, MMST, PDQ39), pre and postoperative videoducumentation, comorbidities, labresults, Levodopaequiveleny dosage, cerebral MRI and CT, localization date of the electrodes, adverse events and severe adverse events, side effects of the stimulation, settings of deep brain stimulation (chosen contacts, impedance, amplitude, pulse width, frequence) from the clinical routine.

—

Secondary

Measure	Time frame
Differentiation of patients with respect to the study's primary endpoints based on age at disease onset, genotype or phenotype, and response to deep brain stimulation (DBS).	—

Countries

Germany

Contacts

Public ContactPatricia Krause

Charité-Universitätsmedizin Berlin, Klinik für Neurologie, Hochschulambulanz für Bewegungsstörungen

patricia.krause@charite.de030450660454

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026